AKEBIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.33 USD | -2.92% |
|
-4.32% | +7.26% |
| Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
| Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Chart calendar Akebia Therapeutics, Inc.
1842f315d057bed04ff.cnMb6DZXRPgBrsrIpMlt-vDGmZGoR7JpLLOxBBnjztY.NDx03GFndrNb4Z6h9vongLr2-qbDHf9ZRsfDTyuHjIwFKXaNGwgMrm_Yjw~1fbfc3459f126f7bf8ecd52b876041c3
Upcoming events on Akebia Therapeutics, Inc.
Past events on Akebia Therapeutics, Inc.
| 2024-03-28 08:00 am | Vafseo FDA Approval Call |
| 2024-03-14 04:15 pm | Q4 2023 Earnings Release |
| 2024-01-11 02:15 pm | JPMorgan Healthcare Conference |
| 2023-11-28 10:30 am | Piper Sandler Healthcare Conference |
| 2023-11-08 08:00 am | Q3 2023 Earnings Call |
| 2023-11-08 07:30 am | Q3 2023 Earnings Release |
| 2023-11-02 12:00 pm | American Society of Nephrology Kidney Conference - Poster Board #: TH-PO139 |
| 2023-11-02 12:00 pm | American Society of Nephrology Kidney Conference - Poster Board #: TH-PO973 |
| 2023-11-02 12:00 pm | American Society of Nephrology Kidney Conference - Poster Board #: INFO12-TH |
| 2023-11-02 10:00 am | American Society of Nephrology Kidney Conference - Poster Board #: TH-PO967 |
| 2023-11-01 | American Society of Nephrology Kidney Conference - Poster Board #: TH-PO983 |
| 2023-09-11 09:30 am | H.C. Wainwright Global Investment Conference |
| 2023-08-25 09:00 am | Q2 2023 Earnings Call |
| 2023-08-25 08:09 am | Q2 2023 Earnings Release |
| 2023-07-25 01:30 pm | H.C. Wainwright Kidney Conference - Fireside Chat |
| 2023-06-07 08:30 am | Jefferies Global Healthcare Conference |
| 2023-06-06 10:00 am | Annual General Meeting |
| 2023-05-30 08:30 am | Vadadustat FDA Approval Update Call |
| 2023-05-08 08:30 am | Q1 2023 Earnings Call |
| 2023-05-08 07:30 am | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 335 359 -6.57% | 295 285 3.44% | 214 206 3.8% | 293 285 2.73% | 195 194 0.38% | 189 |
|
EBITDA Million USD | Released Forecast Spread | -284 -234 -21.56% | -345 -353 2.29% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -286 -242 -18.31% | -376 -347 -8.52% | -265 -252 -5.28% | -63,2 -103 38.95% | -46,1 -53,6 14.01% | -58,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -286 -247 -16.1% | -383 -352 -8.93% | -283 -268 -5.59% | -92,6 -120 22.7% | -51,9 -60,2 13.76% | -60,8 |
|
Net income Million USD | Released Forecast Spread | -280 -242 -15.78% | -383 -352 -8.89% | -283 -269 -5.29% | -92,6 -120 22.7% | -51,9 -59,8 13.18% | -63,4 |
|
EPS USD | Released Forecast Spread | -2,36 -2,03 -16.01% | -2,77 -2,57 -7.95% | -1,70 -1,66 -2.31% | -0,51 -0,65 21.94% | -0,28 -0,32 11.58% | -0,29 |
| Announcement Date | 10/03/20 | 25/02/21 | 01/03/22 | 09/03/23 | 14/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 59,6 51,8 15.13% | 61,7 44,2 39.51% | 127 49,7 155.06% | 49,0 47,2 3.81% | 55,2 47,4 16.42% | 40,1 46,7 -14.05% | 56,4 59,1 -4.61% | 42,0 48,2 -12.74% | 56,2 55,4 1.45% | 46,3 | 49,5 | 43,6 | 49,6 | 43,7 |
|
EBITDA Million USD | Released Forecast Spread | -58,1 -61,0 4.79% | |||||||||||||
|
EBIT Million USD | Released Forecast Spread | -66,2 -52,9 -25.16% | -58,5 -49,4 -18.4% | 48,4 -57,0 184.98% | -48,0 -23,3 -105.9% | -5,13 -30,7 83.31% | -24,8 -24,6 -0.97% | -9,09 -3,81 -138.36% | -12,9 -14,6 11.76% | 1,37 -6,46 121.27% | -13,7 | -11,1 | -17,5 | -16,1 | -10,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -70,7 -56,3 -25.5% | -62,4 -53,5 -16.64% | 29,3 -60,6 148.3% | -51,9 -27,8 -86.5% | -7,55 -34,7 78.26% | -26,2 -28,1 6.68% | -11,2 -5,19 -115.32% | -14,5 -15,9 9.06% | 0,61 -8,64 107.1% | -17,5 | -14,8 | -18,0 | -10,5 | 8,76 |
|
Net income Million USD | Released Forecast Spread | -70,7 -56,3 -25.5% | -62,4 -53,5 -16.64% | 29,3 -60,6 148.3% | -51,9 -27,8 -86.5% | -7,55 -34,7 78.26% | -26,2 -28,1 6.68% | -11,2 -5,19 -115.32% | -14,5 -15,9 9.06% | 0,61 -7,97 107.7% | -14,8 | -12,3 | -18,8 | -17,5 | -11,6 |
|
EPS USD | Released Forecast Spread | -0,40 -0,31 -29.03% | -0,35 -0,29 -21.27% | 0,15 -0,33 145% | -0,28 -0,15 -93.1% | -0,04 -0,19 78.57% | -0,14 -0,15 6.67% | -0,06 -0,03 -140% | -0,08 -0,09 5.88% | 0,00 -0,04 - | -0,08 | -0,06 | -0,08 | -0,07 | -0,05 |
| Announcement Date | 01/03/22 | 09/05/22 | 04/08/22 | 03/11/22 | 09/03/23 | 08/05/23 | 25/08/23 | 08/11/23 | 14/03/24 | - | - | - | - | - |
More events
Past sector events for Akebia Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AKBA Stock
- Calendar Akebia Therapeutics, Inc.
